Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at DKK 558.1B, ahead of Gilead Sciences (DKK 248B) and Biogen (DKK 76.2B). Figures as of 18 Nov 2026, 14:23 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenDKK 558.1B
- Median
- DKK 4.8B
- Combined market value
- DKK 5.78T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | DKK 558.1B | DKK 1.69T | DKK 3,119.47 | 0.95% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | DKK 248B | DKK 1.44T | DKK 1,159.83 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | DKK 76.2B | DKK 252.5B | DKK 1,708.41 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | DKK 25.1B | DKK 570B | DKK 1,408.74 | 3.93% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | DKK 20.9B | DKK 143.3B | DKK 578.08 | 0.47% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | DKK 17.1B | DKK 70B | DKK 338.90 | 0.12% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | DKK 16.9B | DKK 74.5B | DKK 653.76 | 0.55% down | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | DKK 9.4B | DKK 114.4B | DKK 1,130.27 | 0.37% up | 20% up | ||
| 9 | argenxARGX · Health Care | DKK 9.3B | DKK 405.9B | DKK 6,454.61 | 0.36% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | DKK 6.8B | DKK 45.4B | DKK 42.64 | 4.68% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | DKK 5.7B | DKK 70.6B | DKK 1,104.79 | 0.37% down | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | DKK 4.9B | DKK 239.7B | DKK 1,108.26 | 2.50% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | DKK 4.7B | DKK 113.9B | DKK 466.63 | 2.09% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | DKK 3.3B | DKK 77.7B | DKK 494.76 | 0.22% down | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | DKK 2.3B | DKK 26.5B | DKK 273.51 | 0.54% down | 21% down | ||
| 16 | VaxcytePCVX · Health Care | DKK 2.2B | DKK 64.1B | DKK 404.64 | 3.59% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | DKK 2B | DKK 31.4B | DKK 194.08 | 2.22% up | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | DKK 1.3B | DKK 43.1B | DKK 659.41 | 3.90% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | DKK 1.2B | DKK 52B | DKK 762.96 | 6.63% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | DKK 1.1B | DKK 70.7B | DKK 827.81 | 3.44% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | DKK 1.1B | DKK 37.5B | DKK 307.09 | 1.21% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | DKK 778.2M | DKK 60.3B | DKK 2,033.76 | 0.22% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | DKK 711.3M | DKK 46.8B | DKK 226.23 | 0.21% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | DKK 265.6M | DKK 48B | DKK 537.75 | 6.89% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 6.8121 DKK).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (DKK 558.1B), Gilead Sciences (DKK 248B) and Biogen (DKK 76.2B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 14:23 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of DKK 5.78T as of 18 Nov 2026, 14:23 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.